BBVA : No turn-around in sight
Entry price | Target | Stop-loss | Potential |
---|
€6.18 |
€6.84 |
€5.77 |
+10.75% |
---|
The underlying tendency is to the upside for shares in Banco Bilbao Vizcaya Argentaria, S.A. and the timing is opportune to get back into the stock. A comeback of the upward dynamic can be anticipated.
Summary● The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths● The company's profit outlook over the next few years is a strong asset.
● The group's high margin levels account for strong profits.
● With a P/E ratio at 9.97 for the current year and 9.56 for next year, earnings multiples are highly attractive compared with competitors.
● The company's share price in relation to its net book value makes it look relatively cheap.
● The company is one of the best yield companies with high dividend expectations.
● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
● Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
● The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
● The group usually releases upbeat results with huge surprise rates.
Weaknesses● As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.